1. Assessment of ursolic acid effect on in vitro model of cardiac fibrosis.
- Author
-
Hosseiny SS, Esmaeili Z, and Neshati Z
- Subjects
- Animals, Cells, Cultured, Myocardium pathology, Myocardium metabolism, Transforming Growth Factor beta1 metabolism, Transforming Growth Factor beta1 genetics, Collagen Type III metabolism, Collagen Type III genetics, Superoxide Dismutase metabolism, Apoptosis drug effects, Animals, Newborn, Matrix Metalloproteinase 2 metabolism, Matrix Metalloproteinase 2 genetics, Actins metabolism, Actins genetics, Malondialdehyde metabolism, Hydroxyproline metabolism, Collagen Type I metabolism, Collagen Type I genetics, NF-E2-Related Factor 2 metabolism, NF-E2-Related Factor 2 genetics, Rats, Triterpenes pharmacology, Ursolic Acid, Fibrosis, Angiotensin II toxicity, Rats, Sprague-Dawley, Fibroblasts drug effects, Fibroblasts metabolism
- Abstract
This study aimed to evaluate the effects of ursolic acid (UA) on Angiotensin II (Ang II)-treated neonatal rat cardiac fibroblasts (rCFs) as an in vitro model of cardiac fibrosis. The rCFs were isolated from two-day-old neonatal rats. An in vitro model of cardiac fibrosis was established using 500 nm Ang II treatment for 48 h. The cells were then treated with 5 and 10 μM of UA for 24 and 48 h. Masson's trichrome staining, hydroxyproline content assay, scratch assay, apoptosis assay, measurements of superoxide dismutase (SOD) and malondialdehyde (MDA) levels, real-time PCR, immunocytology and western blotting, were employed to assess the impact of UA. Ang II induced fibrosis in rCFs, as evidenced by the examination of various fibrotic markers. Upon treatment with 5 and 10 μM of UA, the amount of fibrosis in Ang II-treated rCFs was significantly decreased, so that the hydroxyproline concentration was reduced to 0.3 and 0.7 times, respectively. The RNA expression of the Col1a1, Col3a1, Tgfb1, Acta2 and Mmp2 genes had a decrease as well as Nrf2 and HO-1 had an increase after UA treatment. UA could lessen the harmful effects of cardiac fibrosis in a dose- and time-dependent manner, due to its antiapoptotic, antioxidant and cardioprotective properties. This suggests the potential of UA for treatment of cardiac fibrosis., Competing Interests: Declaration of competing interest The authors have no conflict of interest., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF